Research institution
Zhejiang Cancer Hospital Clinical Trials
Studies where Zhejiang Cancer Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 76Breast Cancer
Pucotenlimab and Anlotinib in Combination With Chemotherapy
A prospective, multicenter, single-arm clinical study enrolling patients with histologically confirmed invasive carcinoma, clinical stage II-III, known PD-L1 status, and treatment-naïve triple-negative breast cancer.
- Trial name
- NCT07896668
- Testing
- LP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Zhejiang Cancer Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Thrombocytopenia, Cancer Treatment-induced Thrombocytopenia
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
This study is a prospective, single-center, open-label, single-arm clinical trial to assess the safety and efficacy of umbilical cord blood in cancer treatment-induced thrombocytopenia (CTIT) patients.
- Trial name
- NCT07441720
- Testing
- umbilical cord blood
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC)
Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
This prospective observational study aims to evaluate the efficacy and safety of anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for patients with advanced gastric…
- Conditions
- Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC), Ascites, Malignant
- Trial name
- NCT07855640
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly…
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Trial name
- BEACON-OLD (NCT07849712)
- Testing
- Benmelstobart Combined With Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Cancinoma (NPC)
Platinum-Free Regimen in Nasopharyngeal Carcinoma
This study aimed to investigate the efficacy of a platinum-free neoadjuvant regimen (gemcitabine, camrelizumab, endostar, and low-dose radiotherapy) followed by a risk-adapted therapeutic strategy in patients with locally…
- Trial name
- NCT07794488
- Testing
- Endostar (recombinant human endostatin injection)
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer Peritoneal Metastasis (GCPM)
A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
This study is a prospective, single-center, open-label, exploratory phase II clinical trial aimed at evaluating the safety, tolerability, and preliminary efficacy of low-dose radiotherapy (LDR) sequentially combined with…
- Trial name
- NCT07784413
- Testing
- low-dose radiotherapy (LDR) sequentially combined with serplulimab, bevacizumab analog, and irinotecan or albumin-bound paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Breast Cancer, HER2-negative Breast Cancer
Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-tumor activity of metronomic oral paclitaxel solution in patients with advanced HER2-negative breast cancer who have previously…
- Trial name
- NCT07602907
- Testing
- Paclitaxel Oral Solution (50mg/qd), Paclitaxel Oral Solution (100mg/TIW), Paclitaxel Oral Solution (OTD)
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancer, Radiation
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Primary Objectives： Evaluate the complete response rate (CR rate) and safety of short - course radiotherapy combined with ivonesimab (AK112) in patients with pMMR/MSS mid - low rectal cancer.
- Conditions
- Rectal Cancer, Radiation, AK112
- Trial name
- STAR (NCT07162714)
- Testing
- radiotherapy, Ivonescimab (20mg/kg Q3W), Non-operative Management
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Uterine Cervical Neoplasms
Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer
This study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer.
- Trial name
- NCT07702838
- Testing
- Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Completed, with results posted
All 1Lymph Node, Breastcancer
CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer
To establish a predicting system on axillary lymph node metastasis based on peripheral blood CK19mRNA and contrast-enhanced ultrasound.
- Trial name
- CK-CEUS (NCT02992067)
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Zhejiang Cancer Hospital